Complex Disorders Alliance
Complex Disorders Alliance (CODA) is a 501(c)(3) patient-founded nonprofit that funds and coordinates AI-driven neuroimmune research across Long COVID, ME/CFS, POTS, and related complex chronic disorders, serving patients, researchers, clinicians, and disease foundations through collaborative studies, registries, and clinical trials.
- Company typePrivate
- Founded2024
- HeadquartersStamford, United States
- Headcount1–10
- GTM typeB2C
- OfferingServices
What Complex Disorders Alliance does
Complex Disorders Alliance (CODA) is a 501(c)(3) patient-founded nonprofit research organization headquartered in Stamford, Connecticut, that funds and coordinates neuroimmune research on complex chronic disorders including Long COVID, ME/CFS, POTS, EDS/HSD, MCAS, chronic migraine, and endometriosis. Founded in 2024 by Fidji Simo (CEO of Instacart, diagnosed with POTS in 2019) and led by CEO Amy Rochlin, CODA operates across five interconnected neuroimmune research domains: neuroimmune signaling, immune network dysregulation, viral and microbial persistence, CSF/glymphatics/cerebral blood flow, and structural mechanics/instability.
CODA's technical core is an AI-driven multi-omics analytics and patient sub-typing platform that integrates genetic data, immune profiling, clinical questionnaires, and wearable data to identify computable phenotypes and biologically informed patient subgroups. The organization builds proprietary value through research programs (MetX registry and biorepository, MELO genomic study, CODA CCD Initiative, Microvascular and Endothelial Research Initiative, Sequence ME & Long COVID whole-genome program), clinical trials (Anktiva, Inspiritol, Vagus Nerve Modulation), and the Solve Together patient data platform managed under its Brain Inflammation Collaborative partnership. AI and combinatorial analytics are primarily delivered through partnerships with PrecisionLife, ChronicleBio, CareEvolution, and academic medical centers including MIT, Stanford, Johns Hopkins, Brown, Edinburgh, Stellenbosch, and Nova Southeastern.
CODA does not sell products or services. Its revenue model is philanthropic: voluntary donations (processed via GiveButter), grants from partner foundations such as the Metrodora Foundation, and co-funding for government-backed research programs (e.g., £4.75M UK government funding for Sequence ME & Long COVID). Customers are not commercial buyers but rather three stakeholder groups: patients participating in registries and trials, researchers and clinicians using the data platform, and research foundations and disease organizations collaborating within the alliance. The organization operates on a community-led, non-commercial go-to-market model focused on building the richest longitudinal dataset for complex disorders to de-risk downstream biotech and pharma investment.
Complex Disorders Alliance firmographics
Firmographics- Name
- Complex Disorders Alliance
- Legal name
- Complex Disorders Alliance
- Website
- https://complexdisorders.org
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Complex Disorders Alliance (CODA) is a 501(c)(3) patient-founded nonprofit that funds and coordinates AI-driven neuroimmune research across Long COVID, ME/CFS, POTS, and related complex chronic disorders, serving patients, researchers, clinicians, and disease foundations through collaborative studies, registries, and clinical trials.
- Ownership category
- akta.pro rank
Complex Disorders Alliance industry classification
Industry- Product category
- Nonprofit Medical Research
- NAICS
- Other Similar Organizations (except Business, Professional, Labor, and Political Organizations) (813990)
- SIC
- Services-Health Services (8000), Services-Misc Health & Allied Services, Nec (8090)
- akta.pro primary industry
- Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA)
- akta.pro secondary industries
- Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM), Global Health Research, Evidence & Technical Assistance Organizations (HLAJAKAN)
Keywords
Where Complex Disorders Alliance is headquartered
LocationHeadquarters
- HQ city
- Stamford
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Complex Disorders Alliance business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Revenue model
- Philanthropic Donations: CODA accepts charitable donations from individuals, foundations, and organizations to fund neuroimmune research programs. Donations are voluntary and non-refundable, processed through secure third-party payment platforms.
- Research Grants and Foundation Funding: CODA receives funding from partner foundations and research grants to support specific studies and clinical initiatives, including collaborations with Metrodora Foundation and other institutional partners.
Go-to-market motion1 record
Distribution channels4 records
Marketing channels6 records
Complex Disorders Alliance product offering
Product offeringCore offering
Complex Disorders Alliance (CODA) is a 501(c)(3) patient-founded nonprofit that funds, coordinates, and accelerates neuroimmune research for complex chronic disorders including Long COVID, ME/CFS, POTS, EDS/HSD, MCAS, chronic migraine, and endometriosis. The organization operates integrated research programs, patient registries, biorepositories, and clinical studies through alliances with academic centers, disease foundations, and biotech partners, applying AI-driven multi-omics analytics for patient subtyping and therapeutic development.
Product overview
CODA (Complex Disorders Alliance) is a 501(c)(3) nonprofit patient-founded research organization that operates as a patient-driven research ecosystem focused on accelerating neuroimmune research for complex chronic disorders. Rather than a traditional product company, CODA functions as a research accelerator providing multiple integrated research programs, clinical studies, and initiatives. The portfolio includes: CODA CCD Initiative (craniocervical dysfunction research), the MELO Study (genetic subtyping collaboration with PrecisionLife), MetX Study (patient registry and biorepository at Metrodora Institute), multiple clinical trials (Anktiva, Inspiritol, Vagus Nerve Modulation), the Sequence ME & Long COVID genomic program, and the CODA Fellowships. CODA Sub-Typing serves as the AI-driven analytical framework across all programs. CODA also participates in the Solve Together platform (managed by Brain Inflammation Collaborative). All programs focus on five interconnected neuroimmune research domains: neuroimmune signaling, immune network dysregulation, viral and microbial persistence, CSF/glymphatics/cerebral blood flow, and structural mechanics/instability.
Differentiator
Problem solved
Functional benefit
Brands
- CODA CCD (Craniocervical Dysfunction Initiative): Research initiative investigating how altered neuroimmune signaling at the craniocervical junction contributes to complex chronic disorders
- CODA Microvascular and Endothelial Research Initiative
- MetX Study
- MELO Study
Products and services
- CODA CCD (Craniocervical Dysfunction) Initiative A landmark research initiative investigating how altered neuroimmune signaling at the craniocervical junction contributes to initiation and progression of complex chronic disorders; encompasses the Modified Delphi Process, Sub-Typing Initiative, Glymphatics Study, and Multi-Center Tissue Study for researchers and patient communities.
- MELO Study A collaborative study combining patient-reported data and genomic analysis to identify risk factors and disease subtypes for ME/CFS and Long COVID, pairing ChronicleBio clinical infrastructure with PrecisionLife AI-driven disease modeling to determine biological subtypes and predictive genetic risk patterns.
- MetX Study A landmark study at Metrodora Institute that established a patient registry, biorepository, and core infrastructure to support future multi-omics research in complex disorders.
- Sequence ME & Long COVID The world's largest long-read, whole-genome sequencing study analyzing complete genetic code of 9,000 people with ME and 9,000 people with Long COVID to identify rare and structural genetic changes underlying these conditions; CODA participates as a funding partner.
- CODA Microvascular and Endothelial Research Initiative Translational research program focused on venous and microvascular blood flow problems, inflammation, and reduced oxygen delivery in complex neuroimmune disorders including Long COVID and ME/CFS, led by Professor Resia Pretorius at Stellenbosch University.
- Anktiva Open Label Mechanistic Study Open label study evaluating Anktiva (IL-15 superagonist immunotherapy) in patients with complex neuroimmune disorders, investigating immune mechanisms, biologic response, and clinical signals while building a characterized longitudinal patient dataset and biorepository.
- Inspiritol Phase I/2b Clinical Trial Phase 1/2b randomized clinical trial evaluating Inspiritol, a proprietary nebulized immunomodulatory therapy, in ME/CFS and Long COVID patients, assessing safety, biologic response, and early clinical efficacy with longitudinal immune profiling.
- CODA Fellowships Fellowship programs supporting researchers working across neuroimmune research domains to advance subtyping, integrate data, and connect biological insight to therapeutic strategy.
- Solve Together Patient Database Platform Dynamic patient database platform created by CareEvolution allowing users to track symptoms, sync wearables, generate reports for providers, and opt into clinical studies; the largest database of its kind in the U.S. for ME/CFS and related conditions, managed by Brain Inflammation Collaborative.
Quantifiable outcome
- 88% of long COVID genetic risk factors identified in UK cohort successfully replicated in US All of Us dataset across diverse ancestries
- +2 more outcomes
Companies that use Complex Disorders Alliance
Customer profileSegments3 records
Ideal customer profiles3 records
Complex Disorders Alliance technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature3 records
Complex Disorders Alliance partnerships and signals
Strategic signalPartnerships
14 partnerships are on record, tiered core and supporting.
- Stellenbosch UniversitycoreProfessor Resia Pretorius at Stellenbosch University leads CODA-supported microvascular research investigating fibrinaloid microclots, hyperactivated platelets, and inflammation-endothelial injury cycles in Long COVID and ME/CFS.
- Massachusetts Institute of Technology (MIT)coreDr. Mikki Tal at MIT leads the MAESTRO study and collaborates with Stellenbosch University on microvascular research. MIT research focuses on shared immune mechanisms across conditions, sex-based differences in immune response, and predictive diagnostics for complex chronic disorders.
- Solve M.E.coreSolve M.E. is a national nonprofit dedicated to ME/CFS, Long Covid, and IACCIs. CODA partners with Solve M.E. to share patient data, accelerate research, and drive faster diagnoses and treatments. Solve M.E.'s Solve Together patient database platform is being managed by Brain Inflammation Collaborative with data shared with CODA and ChronicleBio.
- Brain Inflammation Collaborative (BIC)coreBIC is a patient-centered nonprofit taking over management of the Solve Together platform from Solve M.E., expanding it to include pediatric populations and additional diagnoses. BIC will help illuminate links between brain inflammation and mental health, with materials translated into Spanish.
- ChronicleBiocoreChronicleBio is a biotech company building an AI-ready data platform for chronic illness. They receive Solve M.E.'s patient data to fuel clinical trials and build the world's most comprehensive longitudinal dataset for ME/CFS, Long COVID, and related conditions.
- CareEvolutionsupportingCareEvolution is a health data and digital clinical research platform provider with 15+ years of healthcare interoperability experience. They created the Solve Together platform that enables symptom tracking, wearable syncing, and clinical study enrollment.
- PrecisionLifecorePrecisionLife provides combinatorial analytics platform for genetic analysis of Long COVID and ME/CFS. Their AI-driven technology identified and reproduced genetic risk factors across US and UK populations with diverse ancestries, supporting drug repurposing and diagnostic development.
- Metrodora Foundation / Metrodora InstitutecoreMetrodora Foundation funds flagship clinical programs (MetX and MELO studies) at Metrodora Institute. CODA collaborates on the MELO Study to identify biomarkers in ME/CFS and Long COVID, combining patient data with PrecisionLife's genetic analysis for precision diagnostics and drug discovery.
- Action for MEsupportingAction for ME leads the Sequence ME & Long COVID study in partnership with the University of Edinburgh and Oxford Nanopore Technologies. Multiple organizations including CODA, Solve ME/CFS, and Schmidt Initiative for Long COVID co-funded initial phase, catalyzing £4.75M in UK government funding.
- Nova Southeastern UniversitysupportingDr. Nancy Klimas at Nova Southeastern University serves as Principal Investigator for the Anktiva open label mechanistic study evaluating IL-15 superagonist immunotherapy in patients with complex neuroimmune disorders.
- University of EdinburghsupportingUniversity of Edinburgh partners with Action for ME and Oxford Nanopore Technologies on Sequence ME & Long COVID, the world's largest long-read whole-genome sequencing study analyzing genetic code of 18,000 participants.
- Oxford Nanopore TechnologiessupportingOxford Nanopore Technologies provides long-read whole-genome sequencing technology for Sequence ME & Long COVID study, enabling analysis of rare and structural genetic changes in ME/CFS and Long COVID patients.
- The Multiple Myeloma Research Foundation (MMRF)supportingMMRF serves as a research model reference for CODA. MMRF transformed cancer research by building collaborative tissue banks, sequencing first cancer genome, and launching nearly 100 trials, helping approve over 15 new drugs.
- Solve ME/CFS InitiativesupportingSolve ME/CFS Initiative is a nonprofit partner that jointly supported the initial phase of Sequence ME & Long COVID research, contributing to the £4.75M UK government funding for genome sequencing of ME/CFS and Long COVID patients.
Scale indicators10 records
Recent moves6 records
Expansion highlights12 records
Complex Disorders Alliance competitors and assessment
Company assessmentDirect peers
- Action for ME: UK-based ME charity leading the Sequence ME & Long COVID whole-genome sequencing study alongside University of Edinburgh and Oxford Nanopore — a direct partner/peer of CODA in the same genomics program and broader ME research ecosystem.
- PolyBio Research Foundation: Nonprofit supporting Long COVID and ME/CFS research with a focus on persistent infection, microvascular pathology, and immune dysfunction — overlapping directly with CODA's microvascular and viral persistence research domains.
- Open Medicine Foundation: Nonprofit that funds and coordinates multi-site ME/CFS and Long COVID research with a focus on collaborative science, biomarker discovery, and clinical translation — closely aligned with CODA's cross-condition research accelerator approach.
- Bateman Horne Center: Clinical care and research center specializing in ME/CFS, Long COVID, and related complex disorders, running patient registries, clinician training, and clinical trials that overlap directly with CODA's research domains.
- Schmidt Initiative for Long COVID: Major philanthropic initiative funding Long COVID research and co-funder of the Sequence ME & Long COVID program — a direct funding peer to CODA in the same disease space.
- Metrodora Foundation: Foundation funding the MetX patient registry/biorepository and MELO biomarker study at Metrodora Institute in collaboration with CODA and PrecisionLife — a direct peer/partner operating in the same neuroimmune research stack.
- Brain Inflammation Collaborative: Patient-centered nonprofit focused on brain inflammation in complex chronic illness that now manages the Solve Together data platform under the multi-party alliance with CODA and Solve M.E.
- Pandemic Patients: Patient advocacy and research nonprofit focused on Long COVID and post-infection chronic illness — closely comparable to CODA in patient-led research mobilization and coalition building.
- Solve M.E. (Solve ME/CFS Initiative): Long-standing national nonprofit dedicated to ME/CFS and Long COVID that operates disease-specific research programs, the Solve Together patient registry, and advocacy — a near-perfect direct peer to CODA in both mission and operating model.
Broad incumbents
- Multiple Myeloma Research Foundation: Mature disease-specific nonprofit explicitly cited by CODA as the operating model for its research accelerator strategy; operates tissue banks, sequencing programs, and nearly 100 trials that helped approve 15+ drugs — the gold-standard analog for what CODA aspires to build in neuroimmune disorders.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Complex Disorders Alliance social profiles
Digital presenceComplex Disorders Alliance financial estimates
Financial estimateRevenue estimate
Valuation estimate
Complex Disorders Alliance leadership team
Management profileNumber of profiles
Profiles5 records
Complex Disorders Alliance funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Complex Disorders Alliance M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Complex Disorders Alliance
What does Complex Disorders Alliance do?
Complex Disorders Alliance (CODA) is a 501(c)(3) patient-founded nonprofit that funds, coordinates, and accelerates neuroimmune research for complex chronic disorders including Long COVID, ME/CFS, POTS, EDS/HSD, MCAS, chronic migraine, and endometriosis. The organization operates integrated research programs, patient registries, biorepositories, and clinical studies through alliances with academic centers, disease foundations, and biotech partners, applying AI-driven multi-omics analytics for patient subtyping and therapeutic development.
Is Complex Disorders Alliance a public or private company?
Complex Disorders Alliance is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was Complex Disorders Alliance founded?
Complex Disorders Alliance was founded in 2024. It employs 1 to 10 people.
Where is Complex Disorders Alliance based?
Complex Disorders Alliance is headquartered in Stamford, United States, in the North America region.
How does Complex Disorders Alliance make money?
Two revenue lines are on record. Philanthropic Donations are the primary driver. The others are research Grants and Foundation Funding.
Who are Complex Disorders Alliance's main competitors?
Direct peers on record are Action for ME, PolyBio Research Foundation, Open Medicine Foundation, Bateman Horne Center, Schmidt Initiative for Long COVID, Metrodora Foundation, Brain Inflammation Collaborative, Pandemic Patients and Solve M.E. (Solve ME/CFS Initiative). Multiple Myeloma Research Foundation is listed as a broad incumbent.
Does Complex Disorders Alliance have an API?
No public API is recorded for Complex Disorders Alliance.
What industry is Complex Disorders Alliance in?
Complex Disorders Alliance's product category is Nonprofit Medical Research. Its primary akta.pro industry code is BPAGACAA, Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS), with a secondary code of HLAJAOAM, Global Health Research, Clinical Trials & Product Development Partnerships (PDPs). Its NAICS code is 813990 and its SIC code is 8000.